Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abeona Therapeutics (ABEO) Gains from Sales and Divestitures: 2022-2024

Historic Gains from Sales and Divestitures for Abeona Therapeutics (ABEO) over the last 3 years, with Dec 2024 value amounting to $1.0 million.

  • Abeona Therapeutics' Gains from Sales and Divestitures rose 43.25% to $1.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.4 million, marking a year-over-year increase of 43.25%. This contributed to the annual value of $1.0 million for FY2024, which is 273.05% up from last year.
  • Per Abeona Therapeutics' latest filing, its Gains from Sales and Divestitures stood at $1.0 million for FY2024, which was up 273.05% from $270,550 recorded in FY2023.
  • Over the past 5 years, Abeona Therapeutics' Gains from Sales and Divestitures peaked at $1.0 million during FY2024, and registered a low of $27,526 during FY2022.
  • Over the past 3 years, Abeona Therapeutics' median Gains from Sales and Divestitures value was $270,550 (recorded in 2023), while the average stood at $435,791.
  • Data for Abeona Therapeutics' Gains from Sales and Divestitures shows a peak YoY soared of 882.89% (in 2023) over the last 5 years.
  • Abeona Therapeutics' Gains from Sales and Divestitures (Yearly) stood at $27,526 in 2022, then soared by 882.89% to $270,550 in 2023, then skyrocketed by 273.05% to $1.0 million in 2024.